Changing the treatment regimen of adults with HIV who had suppressed viral loads to darunavir-cobicistat-emtricitabine-tenofovir alafenamide (D/C/F/TAF; Symtuza, Janssen Pharmaceuticals) did not increase their viral loads, according to a study presented at IDWeek 2018, in San Francisco (abstract 1768).
The researchers reported on 96-week data from the ongoing international, multicenter, open-label, phase 3 EMERALD study, which is evaluating the efficacy and safety of